Blood Advances (Dec 2019)
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings
- Ann T. Farrell,
- Julie Panepinto,
- Ankit A. Desai,
- Adetola A. Kassim,
- Jeffrey Lebensburger,
- Mark C. Walters,
- Daniel E. Bauer,
- Rae M. Blaylark,
- Donna M. DiMichele,
- Mark T. Gladwin,
- Nancy S. Green,
- Kathryn Hassell,
- Gregory J. Kato,
- Elizabeth S. Klings,
- Donald B. Kohn,
- Lakshmanan Krishnamurti,
- Jane Little,
- Julie Makani,
- Punam Malik,
- Patrick T. McGann,
- Caterina Minniti,
- Claudia R. Morris,
- Isaac Odame,
- Patricia Ann Oneal,
- Rosanna Setse,
- Poornima Sharma,
- Shalini Shenoy
Affiliations
- Ann T. Farrell
- US Food and Drug Administration, White Oak, MD;
- Julie Panepinto
- Pediatric Hematology, Medical College of Wisconsin/Children's Wisconsin, Milwaukee, WI;; Julie Panepinto, Medical College of Wisconsin, 8701 Watertown Plank Rd, MS 756, Milwaukee, WI 53226;
- Ankit A. Desai
- Krannert Institute of Cardiology, Department of Medicine, Indiana University, Indianapolis, IN;
- Adetola A. Kassim
- Division of Hematology/Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN;
- Jeffrey Lebensburger
- Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL;
- Mark C. Walters
- UCSF Benioff Children's Hospital, Oakland, CA;
- Daniel E. Bauer
- Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA;; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;; Department of Pediatrics, Harvard Medical School, Boston, MA;
- Rae M. Blaylark
- Children's Hospitals and Clinics of MN, Minneapolis, MN;; Sickle Cell Foundation of Minnesota, Minneapolis, MN;
- Donna M. DiMichele
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
- Mark T. Gladwin
- Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA;
- Nancy S. Green
- Department of Pediatrics, Columbia University Medical Center, New York, NY;
- Kathryn Hassell
- Division of Hematology, Department of Medicine, University of Colorado, Aurora, CO;
- Gregory J. Kato
- Division of Hematology-Oncology and Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA;
- Elizabeth S. Klings
- The Pulmonary Center, Boston University School of Medicine, Boston, MA;
- Donald B. Kohn
- Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA;; Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA;; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA;
- Lakshmanan Krishnamurti
- Aflac Cancer and Blood Disorders Center, Emory University, Children's Healthcare of Atlanta, Atlanta, GA;
- Jane Little
- Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC;
- Julie Makani
- Department of Haematology and Blood Transfusion, School of Medicine, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania;
- Punam Malik
- Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH;; Department of Pediatrics, University of Cincinnati, Cincinnati, OH;
- Patrick T. McGann
- Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH;; Department of Pediatrics, University of Cincinnati, Cincinnati, OH;
- Caterina Minniti
- Division of Hematology, Montefiore Health System, Albert Einstein College of Medicine, New York, NY;
- Claudia R. Morris
- Division of Pediatric Emergency Medicine, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA;; Children's Healthcare of Atlanta, Atlanta, GA;
- Isaac Odame
- The Hospital for Sick Children, Toronto, ON, Canada;; University of Toronto, Toronto, ON, Canada;
- Patricia Ann Oneal
- US Food and Drug Administration, White Oak, MD;
- Rosanna Setse
- US Food and Drug Administration, White Oak, MD;
- Poornima Sharma
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
- Shalini Shenoy
- Division of Pediatric Hematology Oncology and Stem Cell Transplant, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO
- Journal volume & issue
-
Vol. 3,
no. 23
pp. 4002 – 4020
Abstract
Abstract: To address the global burden of sickle cell disease and the need for novel therapies, the American Society of Hematology partnered with the US Food and Drug Administration to engage the work of 7 panels of clinicians, investigators, and patients to develop consensus recommendations for clinical trial end points. The panels conducted their work through literature reviews, assessment of available evidence, and expert judgment focusing on end points related to patient-reported outcome, pain (non–patient-reported outcomes), the brain, end-organ considerations, biomarkers, measurement of cure, and low-resource settings. This article presents the findings and recommendations of the end-organ considerations, measurement of cure, and low-resource settings panels as well as relevant findings and recommendations from the biomarkers panel.
